Hoping to thrive in a development arena long neglected by Big Pharma, Woburn, MA-based Excelimmune has raised $10.5 million in a Series B to fund its work on an antibody candidate targeting MRSA. The round was provided by a group of unnamed "high net worth" angel investors. "The continued support from investors underscores the significant potential of our unique HRPA approach to treating nosocomial infectious disease," said Quinton Zondervan, the CEO of Excelimmune. "In addition to doubling Excelimmune's size over the past year, this funding provides us with the capital required to enter the next stage of our product and technology development." Excelimmune release